$HPTX News
Last published 1y ago
- 1y agoDVAXMRNASNYTARS+4Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow ShareholdersBusiness WireBelieves Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on
- 1y agoAVTEDVAXHZNPMRNA+7Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual MeetingBusiness WireIssues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom
- 11y agoHPTXLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Hyperion Therapeutics, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ:HPTX) concerning the termination of the development of its Type 1 diabetes drug due to the manipulation of trial data.
- 12y agoHPTXLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Hyperion Therapeutics, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ:HPTX) concerning the termination of the development of its Type 1 diabetes drug due to the manipulation of trial data.
- 14y agoHPTXHyperion Therapeutics Completes Initial Public Offering and Announces Exercise of Underwriters’ Over-Allotment OptionBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hyperion Therapeutics, Inc. (NASDAQ:HPTX) announced today the completion of its initial public offering of 5,000,000 shares of common stock. In addition, the underwriters of its initial public offering exercised their over-allotment option in full and purchased an additional 750,000 shares of common stock. All of such shares were sold by Hyperion Thera ...
- 14y agoHPTXHyperion Therapeutics Announces Pricing of Initial Public OfferingBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hyperion Therapeutics, Inc. (NASDAQ:HPTX) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Hyperion. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 ...